Active clearance of human amyloid beta 1-42 peptide aggregates from the rat ventricular system.
A major constituent of SP in the brains of Alzheimer's disease is 39-43 amino acid peptide called beta-amyloid peptide (Abeta). Recent data have demonstrated that Abeta has a strong tendency to form insoluble aggregates and that toxic effects of Abeta is based on its aggregation. In the current study, 100 microg of human synthetic Abeta 1-42 (sAbeta 1-42) was infused into the lateral ventricle of rat brain using a short-term infusion model. At 2 or 7 days following the infusion, sAbeta 1-42 was found to form insoluble aggregates, scattering throughout the entire ventricular systems. The sAbeta 1-42 aggregates were partially engulfed by phagocytic cells and deposited at the meningeal vessels or the choroid plexuses. However, these deposits mostly disappeared from the ventricles by 28 days post-infusion. Here, it is reported for the first time that considerable amounts of sAbeta 1-42 are almost cleared from the rat ventricular system by the mononuclear phagocytic system.
Nakagawa
Yasushi
Y
Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. DQG04732@nifty.ne.jp
Yuzuriha
Takefumi
T
Iwaki
Toru
T
D000595:Amino Acid Sequence; D016229:Amyloid beta-Peptides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000818:Animals; D002552:Cerebral Ventricles / Q000378:metabolism*; D006801:Humans; D007276:Injections, Intraventricular; D008297:Male; D008657:Metabolic Clearance Rate; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000008:administration & dosage / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar
D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)